Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BRD9500 is an orally active inhibitor of phosphodiesterases 3 (PDE3) with IC 50 s of 10 and 27 nM for PDE3A and PDE3B, respectively. BRD9500 is active in an SK-MEL-3 xenograft model of cancer [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | 6-8 weeks | $ 274.00 | |
25 mg | 6-8 weeks | $ 854.00 | |
50 mg | 6-8 weeks | $ 1,110.00 | |
100 mg | 6-8 weeks | $ 1,700.00 | |
1 mL * 10 mM (in DMSO) | 6-8 weeks | $ 263.00 |
Description | BRD9500 is an orally active inhibitor of phosphodiesterases 3 (PDE3) with IC 50 s of 10 and 27 nM for PDE3A and PDE3B, respectively. BRD9500 is active in an SK-MEL-3 xenograft model of cancer [1]. |
In vitro | As an analog of DNMDP, BRD9500 effectively and selectively targets PDE3A and PDE3B, disrupting cancer cell viability by facilitating the interaction between PDE3A/B and SLFN12. This compound has demonstrated potent activity against the SK-MEL-3 melanoma cell line, with an EC50 of 1 nM, and against HeLa cells, with an EC50 of 1.6 nM. Furthermore, at a concentration of 10 μM over 8 hours, BRD9500 stabilizes the PDE3A-SLFN12 interaction in HeLa cells, evidenced by a Western Blot Analysis. This analysis revealed clear detection of the SLFN12-V5 fusion protein via coimmunoprecipitation and immunoblotting with an anti-V5 antibody, confirming the compound's targeted mechanism of action. |
In vivo | BRD9500, administered orally at dosages of 10, 20, and 50 mg/kg, effectively inhibits the growth of SK-MEL-3 melanoma in mouse models, demonstrating potent antitumor activity, particularly at 50 mg/kg. Notably, it exhibits high plasma concentrations when given either intravenously (iv) at 1 mg/kg or orally (po) at 2 mg/kg, persisting for over eight hours. This pharmacokinetic profile, combined with its tolerability—evidenced by the absence of significant weight loss or toxicities in treated animals—positions BRD9500 as a promising agent for in vivo xenograft experimentation. The study utilized female NMRI nude mice implanted with SK-MEL-3 melanoma cell tumor xenografts, applying oral doses of 10 and 20 mg/kg twice daily and 50 mg/kg once daily, with the highest dose yielding the most pronounced antitumor effects. |
Molecular Weight | 291.32 |
Formula | C15H18FN3O2 |
CAS No. | 1630760-75-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BRD9500 1630760-75-6 inhibitor inhibit